MX2024001331A - Regulador derivado del cicloalqueno, método de preparación de este y su aplicación. - Google Patents
Regulador derivado del cicloalqueno, método de preparación de este y su aplicación.Info
- Publication number
- MX2024001331A MX2024001331A MX2024001331A MX2024001331A MX2024001331A MX 2024001331 A MX2024001331 A MX 2024001331A MX 2024001331 A MX2024001331 A MX 2024001331A MX 2024001331 A MX2024001331 A MX 2024001331A MX 2024001331 A MX2024001331 A MX 2024001331A
- Authority
- MX
- Mexico
- Prior art keywords
- preparation
- application
- cycloalkene
- regulator
- general formula
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110892791 | 2021-08-04 | ||
| CN202111322097 | 2021-11-09 | ||
| CN202210041958 | 2022-01-14 | ||
| CN202210540040 | 2022-05-17 | ||
| PCT/CN2022/110017 WO2023011539A1 (zh) | 2021-08-04 | 2022-08-03 | 环烯类衍生物调节剂、其制备方法和应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024001331A true MX2024001331A (es) | 2024-04-19 |
Family
ID=85155248
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024001331A MX2024001331A (es) | 2021-08-04 | 2022-08-03 | Regulador derivado del cicloalqueno, método de preparación de este y su aplicación. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240360109A1 (https=) |
| EP (1) | EP4382525A4 (https=) |
| JP (1) | JP2024529527A (https=) |
| KR (1) | KR20240042624A (https=) |
| CN (1) | CN117751110A (https=) |
| AU (1) | AU2022321506A1 (https=) |
| CA (1) | CA3227366A1 (https=) |
| IL (1) | IL310400A (https=) |
| MX (1) | MX2024001331A (https=) |
| TW (1) | TW202321227A (https=) |
| WO (1) | WO2023011539A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3188891A1 (en) | 2020-09-01 | 2022-01-13 | Fanglong Yang | Fused imidazole derivative, preparation method therefor, and medical use thereof |
| PT4408840T (pt) | 2021-09-27 | 2025-10-07 | Terns Pharmaceuticals Inc | Ácidos benzimidazolocarboxílicos como agonistas de glp-1r |
| CN118401519A (zh) | 2021-10-25 | 2024-07-26 | 拓臻制药公司 | 作为glp-1r激动剂的化合物 |
| CN119095843A (zh) | 2022-02-23 | 2024-12-06 | 拓臻制药公司 | 作为glp-1r激动剂的化合物 |
| TW202434574A (zh) * | 2023-02-02 | 2024-09-01 | 大陸商江蘇豪森藥業集團有限公司 | 一種環烯類化合物的鹽、晶型及其製備方法和應用 |
| EP4568664B1 (en) | 2023-04-07 | 2026-04-01 | Terns Pharmaceuticals, Inc. | Combination comprising a thr-beta agonist and a glp-1r agonist for use in treating obesity |
| CN120981457A (zh) | 2023-09-14 | 2025-11-18 | 歌礼制药(中国)有限公司 | Glp-1r激动剂及其治疗方法 |
| TW202521534A (zh) | 2023-11-24 | 2025-06-01 | 香港商歌禮製藥(中國)有限公司 | Glp-1r 激動劑及其治療方法 |
| WO2025247390A1 (zh) * | 2024-05-31 | 2025-12-04 | 福佑泰生物制药公司 | 可用作glp-1r激动剂的杂双环化合物 |
| WO2025252201A1 (zh) * | 2024-06-07 | 2025-12-11 | 江苏豪森药业集团有限公司 | 一种环烯类衍生物的制备方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016022742A1 (en) * | 2014-08-08 | 2016-02-11 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
| KR102314286B1 (ko) * | 2016-12-16 | 2021-10-21 | 화이자 인코포레이티드 | Glp-1 수용체 작용제 및 이의 용도 |
| US10934279B2 (en) * | 2018-06-13 | 2021-03-02 | Pfizer Inc. | GLP-1 receptor agonists and uses thereof |
| DK3806855T5 (da) * | 2018-06-15 | 2023-05-22 | Pfizer | GLP-1-receptoragonister og anvendelser deraf |
| MA54555A (fr) * | 2018-11-22 | 2021-09-29 | Qilu Regor Therapeutics Inc | Agonistes de glp-1r et leurs utilisations |
| EP3953344A4 (en) * | 2019-04-12 | 2023-08-09 | Qilu Regor Therapeutics Inc. | GLP-IR AGONISTS AND THEIR USES |
| WO2021018023A1 (zh) * | 2019-08-01 | 2021-02-04 | 济南泰达领创医药技术有限公司 | 小分子glp-1受体调节剂 |
| EP4048664A1 (en) * | 2019-10-25 | 2022-08-31 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| WO2021096284A1 (ko) * | 2019-11-15 | 2021-05-20 | 일동제약(주) | Glp-1 수용체 작용제 및 이의 용도 |
| TW202206429A (zh) * | 2020-04-29 | 2022-02-16 | 美商迦舒布魯姆生物有限公司 | 雜環ｇｌｐ—１促效劑 |
| CA3192601A1 (en) * | 2020-08-21 | 2022-02-24 | Terns Pharmaceuticals, Inc. | Compounds as glp-1r agonists |
| CA3188891A1 (en) * | 2020-09-01 | 2022-01-13 | Fanglong Yang | Fused imidazole derivative, preparation method therefor, and medical use thereof |
| EP4229050A4 (en) * | 2020-10-13 | 2024-12-11 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| CN114805336B (zh) * | 2021-01-20 | 2026-04-14 | 江苏恒瑞医药股份有限公司 | 稠合咪唑类化合物、其制备方法及其在医药上的应用 |
-
2022
- 2022-08-03 WO PCT/CN2022/110017 patent/WO2023011539A1/zh not_active Ceased
- 2022-08-03 KR KR1020247006472A patent/KR20240042624A/ko active Pending
- 2022-08-03 IL IL310400A patent/IL310400A/en unknown
- 2022-08-03 JP JP2024506443A patent/JP2024529527A/ja active Pending
- 2022-08-03 MX MX2024001331A patent/MX2024001331A/es unknown
- 2022-08-03 CN CN202280053790.2A patent/CN117751110A/zh active Pending
- 2022-08-03 AU AU2022321506A patent/AU2022321506A1/en active Pending
- 2022-08-03 US US18/293,637 patent/US20240360109A1/en active Pending
- 2022-08-03 CA CA3227366A patent/CA3227366A1/en active Pending
- 2022-08-03 EP EP22852251.2A patent/EP4382525A4/en active Pending
- 2022-08-04 TW TW111129379A patent/TW202321227A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL310400A (en) | 2024-03-01 |
| WO2023011539A1 (zh) | 2023-02-09 |
| EP4382525A4 (en) | 2025-07-16 |
| US20240360109A1 (en) | 2024-10-31 |
| CA3227366A1 (en) | 2023-02-09 |
| JP2024529527A (ja) | 2024-08-06 |
| CN117751110A (zh) | 2024-03-22 |
| KR20240042624A (ko) | 2024-04-02 |
| EP4382525A1 (en) | 2024-06-12 |
| AU2022321506A1 (en) | 2024-02-01 |
| TW202321227A (zh) | 2023-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024001331A (es) | Regulador derivado del cicloalqueno, método de preparación de este y su aplicación. | |
| MX2023012054A (es) | Inhibidor derivado heterociclico y metodo de preparacion y su aplicacion. | |
| JOP20220155A1 (ar) | مشتقات البيرازول مفيدة كعوامل مضادة للسرطان | |
| MX2022004451A (es) | Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1. | |
| ECSP22019360A (es) | Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos | |
| PH12021552782A1 (en) | Modulators of thr-ã and methods of use thereof | |
| BR112022000431A2 (pt) | Derivados de 2-morfolinopiridina substituídos como inibidores da atr cinase | |
| MX2020007633A (es) | Péptidos macrocíclicos contra acinetobacter baumannii. | |
| BR112022005660A2 (pt) | Inibidores de fxia e método de preparação dos mesmos e uso farmacêutico dos mesmos. | |
| MX390747B (es) | Compuesto heterociclico sustituido con alquinilo, su metodo de preparacion y su uso medico. | |
| MX2021003655A (es) | Derivado de indol macrociclico, metodo de preparacion del mismo y aplicacion del mismo en medicina. | |
| MX2022004450A (es) | Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1. | |
| CO2019010078A2 (es) | Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1 | |
| MX389965B (es) | Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos | |
| MX2021010122A (es) | Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos. | |
| BR112021011325A2 (pt) | Derivados de rapamicina | |
| PH12021551232A1 (en) | Haloallylamine compounds and application thereof | |
| MY197561A (en) | Composition for increasing expression of pgc-1? | |
| MX2022008091A (es) | Derivado de tetrahidroisoquinolina triciclica, metodo de preparacion del mismo y aplicacion del mismo en medicina. | |
| BR112023005443A2 (pt) | Derivado de y-carbolina fundido substituído heterocíclico, método de preparação do mesmo, intermediário do mesmo e uso do mesmo | |
| MX2022002603A (es) | Proceso industrial para la preparacion de estetrol de alta pureza. | |
| CL2022001661A1 (es) | Triterpenoides sintéticos con sustituyentes a base de nitrógeno en c-17 y métodos de uso de los mismos | |
| MX2025006915A (es) | Preparación farmacéutica de un compuesto de imidazolinona, método de preparación y uso de esta | |
| MX2025009098A (es) | Sal y forma cristalina de un compuesto cicloalquenico y metodo de preparacion de estos y uso de estos | |
| BR112022004398A2 (pt) | Cristal de derivado de 1,3,5-triazina ou solvato do mesmo e método para produção do mesmo |